Benjamin Maughan, MD, PharmD

Benjamin Maughan, MD, PharmD, of University of Utah Health

Articles by Benjamin Maughan, MD, PharmD

Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.
View More
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel explains how the approval of subcutaneous nivo offers advantages in patient convenience and healthcare efficiency.
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel weighs long-term treatment-free survival with nivo/ipi against the need for disease control with IO-TKI combos.
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel considers the limitations of ctDNA from low tumor shedding but expresses optimism for detection technology.
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel weighs the evolving role of biomarkers, particularly the promising blood-based biomarker KIM-1.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs.